Schizophrenia News and Research

Latest Schizophrenia News and Research

Kynurenic acid levels reduced in suicide attempters with schizophrenia

Cerebrospinal fluid concentrations of kynurenic acid are significantly lower in schizophrenia-spectrum patients with a history of suicide attempts than in those without, researchers report.

13 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

Many pediatric respiratory hospitalizations unnecessary

Study findings suggest that a large number of pediatric hospitalizations, particularly those of a respiratory nature, could be prevented.

11 Sep 2012

Plasma biomarker predicts rheumatoid arthritis onset

Healthy individuals with high levels of immunoglobulin G rheumatoid factor have a significantly increased risk for developing rheumatoid arthritis, suggests population-based research published in the BMJ.

10 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Increased use of powerful antipsychotic drugs to treat publicly insured children

A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012

Phthalates may be asthma trigger

Research suggests that exposure to two phthalates may be a trigger for asthma-related airway inflammation.

7 Sep 2012

Therapeutic targets for pemphigus vulgaris discovered

Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.

7 Sep 2012

Antipsychotic-induced obsessive compulsive symptoms assessed

Results from a Korean study show that the symptom structure of second-generation-antipsychotic-induced obsessive compulsive symptoms is similar to that seen in patients with “pure” obsessive compulsive disorder.

7 Sep 2012

Night eating syndrome increased in schizophrenia patients

The prevalence of night eating syndrome is significantly increased among patients with schizophrenia or schizoaffective disorder who are obese, results from a US study suggest.

6 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

CSHL publishes genome-wide analysis of transcripts produced within human cells

Most people understand genes to be specific segments of DNA that determine traits or diseases that are inherited. Textbooks suggest that genes are copied into RNA molecules, which are then used as templates for making protein - the highly diverse set of molecules that act as building blocks and engines of our cells. The truth, it now appears, is not so simple.

6 Sep 2012

Teenage brains being changed by the digital revolution

The digital revolution appears to be changing the adolescent brain to enable it to cope with constant technological stimulation, says visiting U.S. adolescent brain researcher Dr Jay Giedd.

6 Sep 2012

Inexperienced psychiatrists with HCR-20-C tool more likely to predict violence risk in patients

Inexperienced psychiatrists are less likely than their veteran peers to accurately predict violence by their patients, but a simple assessment checklist might help bridge that accuracy gap, according to new research from the University of Michigan.

6 Sep 2012

Delayed WM growth in siblings of childhood-onset schizophrenia patients

The unaffected adolescent siblings of patients with childhood-onset schizophrenia show reduced white matter growth rates compared with other adolescents, researchers report.

5 Sep 2012

Breastfeeding may lower risk for depression in adulthood

A study published in the last issue of Psychotherapy and Psychosomatics examines the relationship between breastfeeding and onset of depression in adulthood.

5 Sep 2012

Subthreshold metabolic syndrome common in drug-naïve schizophrenia patients

Around 1 in 10 antipsychotic-naïve Indian patients with schizophrenia meet full criteria for the metabolic syndrome, but a significantly larger proportion have subthreshold metabolic syndrome, researchers report.

4 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012